A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Sorafenib (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms SPACE
- Sponsors Bayer
- 22 Jan 2016 Results published in the Journal of Hepatology
- 21 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS0000366).